The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer.
Ahmet Serkan IlgunFatma AktepeOnur GonulluFatma Nilgun KapucuogluKanay YararbaşTuba Kayan TapanAlper OztürkFiliz ElbükenZeynep İyigün ErdoğanÇetin OrduCaglar UnalTomris DuymazGursel SoybirEkrem YavuzSitki TuzlaliVahit ÖzmenPublished in: Future oncology (London, England) (2022)
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: 115 patients with pre-NAC core biopsies and post-NAC surgical resection specimens were reviewed. Results: There was no significant change between pre- and post-treatment sTILs. Both pre- and post-NAC sTILs were significantly lower in patients with luminal A subtype. An increase in sTILs was observed in 21 (25.9%) patients after NAC, a decrease in 29 (35.8%) and no change in 31 (38.3%; p = 0.07). Pretreatment sTIL density was independent predictor of pathological complete response in multivariate analyses (odds ratio: 1.025, 95% CI: 1.003-1.047; p = 0.023). Conclusion: High sTIL density in core biopsies was independently related to pathological complete response. In addition, ER appears to be the most crucial factor determining the rate of sTIL.
Keyphrases
- neoadjuvant chemotherapy
- transcription factor
- locally advanced
- lymph node
- sentinel lymph node
- genome wide analysis
- end stage renal disease
- peripheral blood
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rectal cancer
- prognostic factors
- peritoneal dialysis
- bone marrow
- squamous cell carcinoma
- early stage
- mass spectrometry
- combination therapy
- endoplasmic reticulum
- high resolution
- breast cancer cells